The group’s principal activities include developing platforms and related technologies. The group will enable the discovery of marketable diagnostic markers to aid in the disease susceptibility and drug response areas of cancer. The group is currently developing technologies, which will enable us to identify and prioritize potential diagnostic markers. The group operates from Canada.
